TY - JOUR
T1 - Clinical, laboratory and imaging features of COVID-19
T2 - A systematic review and meta-analysis
AU - Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19)
AU - Rodriguez-Morales, Alfonso J.
AU - Cardona-Ospina, Jaime A.
AU - Gutiérrez-Ocampo, Estefanía
AU - Villamizar-Peña, Rhuvi
AU - Holguin-Rivera, Yeimer
AU - Escalera-Antezana, Juan Pablo
AU - Alvarado-Arnez, Lucia Elena
AU - Bonilla-Aldana, D. Katterine
AU - Franco-Paredes, Carlos
AU - Henao-Martinez, Andrés F.
AU - Paniz-Mondolfi, Alberto
AU - Lagos-Grisales, Guillermo J.
AU - Ramírez-Vallejo, Eduardo
AU - Suárez, Jose A.
AU - Zambrano, Lysien I.
AU - Villamil-Gómez, Wilmer E.
AU - Balbin-Ramon, Graciela J.
AU - Rabaan, Ali A.
AU - Harapan, Harapan
AU - Dhama, Kuldeep
AU - Nishiura, Hiroshi
AU - Kataoka, Hiromitsu
AU - Ahmad, Tauseef
AU - Sah, Ranjit
N1 - Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Introduction: An epidemic of Coronavirus Disease 2019 (COVID-19) began in December 2019 in China leading to a Public Health Emergency of International Concern (PHEIC). Clinical, laboratory, and imaging features have been partially characterized in some observational studies. No systematic reviews on COVID-19 have been published to date. Methods: We performed a systematic literature review with meta-analysis, using three databases to assess clinical, laboratory, imaging features, and outcomes of COVID-19 confirmed cases. Observational studies and also case reports, were included, and analyzed separately. We performed a random-effects model meta-analysis to calculate pooled prevalences and 95% confidence intervals (95%CI). Results: 660 articles were retrieved for the time frame (1/1/2020-2/23/2020). After screening, 27 articles were selected for full-text assessment, 19 being finally included for qualitative and quantitative analyses. Additionally, 39 case report articles were included and analyzed separately. For 656 patients, fever (88.7%, 95%CI 84.5–92.9%), cough (57.6%, 95%CI 40.8–74.4%) and dyspnea (45.6%, 95%CI 10.9–80.4%) were the most prevalent manifestations. Among the patients, 20.3% (95%CI 10.0–30.6%) required intensive care unit (ICU), 32.8% presented with acute respiratory distress syndrome (ARDS) (95%CI 13.7–51.8), 6.2% (95%CI 3.1–9.3) with shock. Some 13.9% (95%CI 6.2–21.5%) of hospitalized patients had fatal outcomes (case fatality rate, CFR). Conclusion: COVID-19 brings a huge burden to healthcare facilities, especially in patients with comorbidities. ICU was required for approximately 20% of polymorbid, COVID-19 infected patients and hospitalization was associated with a CFR of >13%. As this virus spreads globally, countries need to urgently prepare human resources, infrastructure and facilities to treat severe COVID-19.
AB - Introduction: An epidemic of Coronavirus Disease 2019 (COVID-19) began in December 2019 in China leading to a Public Health Emergency of International Concern (PHEIC). Clinical, laboratory, and imaging features have been partially characterized in some observational studies. No systematic reviews on COVID-19 have been published to date. Methods: We performed a systematic literature review with meta-analysis, using three databases to assess clinical, laboratory, imaging features, and outcomes of COVID-19 confirmed cases. Observational studies and also case reports, were included, and analyzed separately. We performed a random-effects model meta-analysis to calculate pooled prevalences and 95% confidence intervals (95%CI). Results: 660 articles were retrieved for the time frame (1/1/2020-2/23/2020). After screening, 27 articles were selected for full-text assessment, 19 being finally included for qualitative and quantitative analyses. Additionally, 39 case report articles were included and analyzed separately. For 656 patients, fever (88.7%, 95%CI 84.5–92.9%), cough (57.6%, 95%CI 40.8–74.4%) and dyspnea (45.6%, 95%CI 10.9–80.4%) were the most prevalent manifestations. Among the patients, 20.3% (95%CI 10.0–30.6%) required intensive care unit (ICU), 32.8% presented with acute respiratory distress syndrome (ARDS) (95%CI 13.7–51.8), 6.2% (95%CI 3.1–9.3) with shock. Some 13.9% (95%CI 6.2–21.5%) of hospitalized patients had fatal outcomes (case fatality rate, CFR). Conclusion: COVID-19 brings a huge burden to healthcare facilities, especially in patients with comorbidities. ICU was required for approximately 20% of polymorbid, COVID-19 infected patients and hospitalization was associated with a CFR of >13%. As this virus spreads globally, countries need to urgently prepare human resources, infrastructure and facilities to treat severe COVID-19.
KW - Clinical features
KW - Coronavirus disease 2019
KW - Epidemic
KW - Laboratory
KW - Outcomes
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85082005057&partnerID=8YFLogxK
U2 - 10.1016/j.tmaid.2020.101623
DO - 10.1016/j.tmaid.2020.101623
M3 - Review article
C2 - 32179124
AN - SCOPUS:85082005057
SN - 1477-8939
VL - 34
JO - Travel Medicine and Infectious Disease
JF - Travel Medicine and Infectious Disease
M1 - 101623
ER -